A Persistent Theory Meets Rigorous Testing
For decades, the idea that the human brain naturally produces dimethyltryptamine — the powerful psychedelic compound known as DMT — has captivated researchers, psychedelic enthusiasts, and neuroscientists alike. The hypothesis gained particular traction through popular culture and speculative scientific writing, with proponents suggesting that endogenous DMT might explain near-death experiences, dreaming, mystical states of consciousness, and other phenomena at the boundary of understood neuroscience.
Central to this theory is the notion that DMT functions as a natural signaling molecule or co-transmitter alongside serotonin in the brain. If true, this would mean that one of the most potent psychedelic substances known to science is not just an exotic plant alkaloid but a routine part of normal brain chemistry, produced and stored in the same neurons that regulate mood, sleep, appetite, and cognition through the serotonin system.
A new study published by researchers from the University of Southern Denmark and Bern University Hospital has now subjected this hypothesis to one of its most rigorous tests to date — and the results are strikingly negative.
What the Researchers Actually Tested
The research team set out to answer two fundamental questions. First, does the rat brain naturally produce detectable levels of DMT? And second, can DMT be taken up and stored in serotonin-releasing neurons through the same transport mechanisms that handle serotonin itself?
These questions matter because the endogenous DMT hypothesis depends on both conditions being true. For DMT to function as a co-transmitter alongside serotonin, it would need to be synthesized in the brain in meaningful quantities and then stored in synaptic vesicles within serotonin neurons, ready for release alongside serotonin during normal neural signaling.
The team analyzed multiple brain regions using highly sensitive quantitative detection methods capable of identifying trace amounts of DMT. To maximize their chances of finding the compound, they also used enzymatic inhibitors that block DMT's metabolic breakdown by monoamine oxidase. If the brain were producing even small amounts of DMT that were being rapidly degraded, blocking that degradation should cause detectable levels to accumulate.
